Heart failure: A paradigm shift on the leading risk factors and opportunities for improving the prognosis
https://doi.org/10.34215/1609-1175-2021-2-25-30
Abstract
Heart failure (HF) is still an urgent problem of the modern society due to constant growth of the both its spread rate and its influence on the disease and death rates. Most patients having HF have a high comorbidity index. Diabetes mellitus (DM) is considered to be one of the most significant and discussed risk factors and diseases influencing the development of HF. There are different opinions on the important role of DM in the development of cardiovascular remodeling in case of HF regardless its phenotype, but there are alternative points of view which refuse the independent role of DM as a risk factor of HF. Inhibitors of type 2 glucose sodium-dependent cotransporters were originally positioned as a means to control glycaemia. They demonstrated cardio-protective effects and reduction of the risk of HF development among patients having DM and better prognosis of the course of disease regardless presence or absence of the type 2 DM.
About the Authors
V. A. Nevzorova
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, professor, head of the Institute of Therapy
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
P. A. Selyukova
Pacific State Medical University
Russian Federation
Russian Federation
MD, post-graduate student of the Institute of Therapy and Instrumental Diagnostics
2 Ostryakova Ave, Vladivostok, 690002, Russian Federation
E. S. Potapova
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, associate professor, Institute of Therapy and Instrumental Diagnostics
2 Ostryakova Ave, Vladivostok, 690002, Russian Federation
References
1. Bokeriya LA, Revishvili AS, Neminushchiy NM. The treatment of the cardiac insufficiency by the method of the cardiac resynchronization. Pacific Medical Journal. 2008;1:5–11 (In Russ).
2. Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life: A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23:1867–76.
3. Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: А study of 1162309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes. 2010;3(6):573–80.
4. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics- 2016 Update: A report from the American Heart Association. Circulation. 2016;133(4):e38–360. doi: 10.1161/CIR.0000000000000350
5. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, Oliveira A. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4(4):531–9.
6. Gomez-Soto FM, Andrey JL, Garcia-Egido AA, Escobar MA, Romero SP, Garcia-Arjona R, et al. Incidence and mortality of heart failure: A community-based study. Int J Cardiol. 2011;151(1):40–5.
7. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77(9):2209–17.
8. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175:996–1004.
9. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.
10. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721–30.
11. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: А population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80.
12. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation. 2009;119(24):3070–7.
13. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42(5):914–22.
14. Boonman-de Winter LJ, Rutten FH, Cramer MJ, MJ, Liem AH, Rutten GEHM, Hoes AW. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154–62.
15. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996–1002.
16. Wang Y, Negishi T, Negishi K, Marwick TH. Prediction of heart failure in patients with type 2 diabetes mellitus – a systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;108(1):55–66.
17. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc.1958;53:457–81.
18. Dedov II. Diabetes mellitus: Development of technologies in diagnosis, treatment and prevention. Diabetes Mellitus. 2010;3:6–13 (In Russ).
19. Vanhecke TE, Kim R, Raheem SZ, McCullough PA. Myocardial ischemia in patients with diastolic dysfunction and heart failure. Curr Cardiol Rep. 2010;12:216–22.
20. Arbolishvili GN, Mareev VYu, Orlova YaA. Belenkov YuN. The relationship of various indicators of rhythm variability with the mechanism of death in patients with chronic heart failure and left ventricular systolic dysfunction. Heart failure. 2006;7(4):172–8 (In Russ).
21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
22. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119(12 Suppl 1):S3–10.
23. Okumura N, Jhund PS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016;133:2254–62.
24. Greene SJ, Butler J, Albert NM, AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351–66.
Review
For citations:
Nevzorova V.A., Selyukova P.A., Potapova E.S. Heart failure: A paradigm shift on the leading risk factors and opportunities for improving the prognosis. Pacific Medical Journal. 2021;(2):25-30. (In Russ.) https://doi.org/10.34215/1609-1175-2021-2-25-30
Views:
404
Email this article 